What the company does
KoBioLabs develops drugs that work by modifying the human microbiome, the community of bacteria and other microorganisms that naturally live in the body and influence health.
It is a clinical-stage biotech listed on KOSDAQ, Korea's tech-focused stock exchange, targeting conditions including immune, metabolic, and neurological diseases. The company handles the full drug-development process in-house, from candidate discovery through clinical trials, and has built a proprietary drug-discovery platform called Smartiome, which it is advancing with AI and multi-omics data.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$24M
- FY2024US$49.5M
- FY2025US$50.2M
Operating profit
- FY2023−US$13.4M
- FY2024−US$5M
- FY2025−US$7M
Net income
- FY2023−US$11M
- FY2024−US$3.3M
- FY2025−US$5.1M
Key ratios (FY2025)
Why it matters · Context, not a recommendation
KoBioLabs claims to have initiated the first global clinical trials for a microbiome-based drug originating in Korea, covering two functional materials for immune diseases.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?